达格列净改善北印度2型糖尿病患者的体脂分布及肝脏和胰腺脂肪
本研究为无对照组的观察性干预配对设计,30例2型糖尿病患者在稳定剂量二甲双胍和/或磺脲类药物基础上加用达格列净10 mg/日治疗120天。结果显示体重、BMI、体脂、各围度及所有皮褶厚度均显著下降,血糖、糖化血红蛋白、肝酶、空腹胰岛素、HOMA-IR及餐后C肽显著降低,HOMA-β、餐后胰岛素敏感性和空腹脂联素显著升高,瘦体重无变化;肝脏脂肪分数从15.2%降至10.1%(P < .0001),胰腺脂肪分数从7.5%降至5.99%(P < .0083)。
要点
- 达格列净10 mg/日治疗120天显著降低2型糖尿病患者的体重、BMI、体脂及所有皮褶厚度。
- 肝脏脂肪分数从15.2%降至10.1%(P < .0001),胰腺脂肪分数从7.5%降至5.99%(P < .0083)。
- 血糖、糖化血红蛋白、肝酶、空腹胰岛素、HOMA-IR及餐后C肽显著降低,HOMA-β、餐后胰岛素敏感性和空腹脂联素显著升高。
核心结论
- 达格列净使用120天后可减少亚洲印度2型糖尿病患者的胰腺和肝脏脂肪并增加胰岛素敏感性。
研究设计与样本
- 本研究为无对照组的观察性干预配对研究设计。
- 共纳入30例2型糖尿病患者,在稳定剂量二甲双胍和/或磺脲类药物基础上给予达格列净10 mg/日,治疗120天。
主要发现
- 治疗120天后,体重、BMI、体脂、各围度及所有皮褶厚度均出现统计学显著下降。
- 血糖、糖化血红蛋白、肝酶、空腹胰岛素、HOMA-IR及餐后C肽均统计学显著降低,而HOMA-β、餐后胰岛素敏感性和空腹脂联素统计学显著升高。
- 瘦体重无变化。
- 与基线相比,平均肝脏脂肪分数从15.2%降至10.1%(P < .0001),平均胰腺脂肪分数从7.5%降至5.99%(P < .0083)。
- 调整体重变化后,肝脏脂肪的减少仍具有统计学显著性。
局限性
- 本研究为无对照组的观察性干预配对研究设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Excess hepatic and pancreatic fat may contribute to hyperglycemia. OBJECTIVE: The objective of this study was to examine the effect of dapagliflozin (an SGLT2 inhibitor) on anthropometric profile, liver, and pancreatic fat in patients with type 2 diabetes mellitus (T2DM). METHODS: This is an observational interventional paired study design without a control group. Patients (n = 30) were given dapagliflozin 10 mg/day (on top of stable dose of metformin and/or sulfonylureas) for 120 days. Changes in anthropometry (circumferences and skinfold thickness), surrogate markers of insulin resistance, body composition, liver, and pancreatic fat (as measured by magnetic resonance imaging (MRI)-derived proton density fat fraction [FF]) were evaluated. RESULTS: After 120 days of treatment with dapagliflozin, a statistically significant reduction in weight, body mass index (BMI), body fat, circumferences, and all skinfold thickness was seen. A statistically significant reduction in blood glucose, glycated hemoglobin A1c, hepatic transaminases, fasting insulin, homeostatic model assessment of insulin resistance (HOMA-IR), and postprandial C-peptide was noted, while HOMA-β, postprandial insulin sensitivity, and fasting adiponectin were statistically significantly increased. There was no change in lean body mass. Compared to baseline there was a statistically significant decrease in mean liver FF (from 15.2% to 10.1%, P < .0001) and mean pancreatic FF (from 7.5% to 5.99%, P < .0083). Reduction in liver fat was statistically significant after adjustment for change in body weight. CONCLUSION: Dapagliflozin, after 120 days of use, reduced pancreatic and liver fat and increased insulin sensitivity in Asian Indian patients with T2DM.
引用
- Ghosh A, Dutta K, Bhatt SP, et al. Dapagliflozin Improves Body Fat Patterning, and Hepatic and Pancreatic Fat in Patients With Type 2 Diabetes in North India. J Clin Endocrinol Metab. 2022. PMID: 35263436. doi:10.1210/clinem/dgac138
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。